Literature DB >> 33827575

The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.

Paolo A Ascierto1, Michael B Atkins2, Alexander M Eggermont3, Jeffrey E Gershenwald4, Jean-Jacques Grob5, Omid Hamid6, Vernon K Sondak7,8, Jeffrey A Sosman9, Hussein A Tawbi10, Jeffrey S Weber11, Corrado Caracò12, Iman Osman13, Igor Puzanov14.   

Abstract

The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd-5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considered whether or not innate immunity is important in the response to cancer and immunotherapy, how useful are the revised American Joint Committee on Cancer (AJCC) classification for the staging of patients, the use of sentinel node biopsy for staging patients, the use of triplet combination of targeted therapy plus immunotherapy versus combined immunotherapy, and the respective benefits of neoadjuvant versus adjuvant therapy. As is usual with Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their own personal opinion.

Entities:  

Keywords:  Adjuvant; Anti-CTLA-4; Anti-PD-1; BRAF inhibitor; Immunotherapy; MEK inhibitor; Melanoma; Neoadjuvant; Staging; Targeted therapy

Year:  2021        PMID: 33827575     DOI: 10.1186/s12967-021-02808-3

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  44 in total

1.  Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

Authors:  Jeffrey Weber; Geoffrey Gibney; Ragini Kudchadkar; Bin Yu; Pingyan Cheng; Alberto J Martinez; Jodie Kroeger; Allison Richards; Lori McCormick; Valerie Moberg; Heather Cronin; Xiuhua Zhao; Michael Schell; Yian Ann Chen
Journal:  Cancer Immunol Res       Date:  2016-02-12       Impact factor: 11.151

2.  Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors:  Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

3.  Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.

Authors:  Mao Lin; Haihua Luo; Shuzhen Liang; Jibing Chen; Aihua Liu; Lizhi Niu; Yong Jiang
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

4.  High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

Authors:  Kobe C Yuen; Li-Fen Liu; Vinita Gupta; Shravan Madireddi; Shilpa Keerthivasan; Congfen Li; Deepali Rishipathak; Patrick Williams; Edward E Kadel; Hartmut Koeppen; Ying-Jiun Chen; Zora Modrusan; Jane L Grogan; Romain Banchereau; Ning Leng; AnnChristine Thastrom; Xiadong Shen; Kenji Hashimoto; Darren Tayama; Michiel S van der Heijden; Jonathan E Rosenberg; David F McDermott; Thomas Powles; Priti S Hegde; Mahrukh A Huseni; Sanjeev Mariathasan
Journal:  Nat Med       Date:  2020-05-11       Impact factor: 53.440

5.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.

Authors:  Kurt A Schalper; Michael Carleton; Ming Zhou; Tian Chen; Ye Feng; Shu-Pang Huang; Alice M Walsh; Vipul Baxi; Dimple Pandya; Timothy Baradet; Darren Locke; Qiuyan Wu; Timothy P Reilly; Penny Phillips; Venkata Nagineni; Nicole Gianino; Jianlei Gu; Hongyu Zhao; Jose Luis Perez-Gracia; Miguel F Sanmamed; Ignacio Melero
Journal:  Nat Med       Date:  2020-05-11       Impact factor: 53.440

6.  Platelets, cardiac valves and sulphinpyrazone.

Authors:  E A Loeliger
Journal:  Thromb Haemost       Date:  1982-04-30       Impact factor: 5.249

7.  A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients.

Authors:  Joseph Cursons; Fernando Souza-Fonseca-Guimaraes; Nicholas D Huntington; Melissa J Davis; Momeneh Foroutan; Ashley Anderson; Frédéric Hollande; Soroor Hediyeh-Zadeh; Andreas Behren
Journal:  Cancer Immunol Res       Date:  2019-05-14       Impact factor: 11.151

8.  Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.

Authors:  Andressa S Laino; David Woods; Melinda Vassallo; Xiaozhong Qian; Hao Tang; Megan Wind-Rotolo; Jeffrey Weber
Journal:  J Immunother Cancer       Date:  2020-06-23       Impact factor: 13.751

9.  Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.

Authors:  Adriana Cordova; Francesca Toia; Carmela La Mendola; Valentina Orlando; Serena Meraviglia; Gaetana Rinaldi; Matilde Todaro; Giuseppe Cicero; Leonardo Zichichi; Paolo Li Donni; Nadia Caccamo; Giorgio Stassi; Francesco Dieli; Francesco Moschella
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

10.  IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients.

Authors:  Richard P Tobin; Kimberly R Jordan; Puja Kapoor; Eric Spongberg; Dana Davis; Victoria M Vorwald; Kasey L Couts; Dexiang Gao; Derek E Smith; Jessica S W Borgers; Steven Robinson; Carol Amato; Rene Gonzalez; Karl D Lewis; William A Robinson; Virginia F Borges; Martin D McCarter
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.